EPISODE · Jan 8, 2025 · 5 MIN
Glaukos Submits NDA for Epi-On CLX Candidate
from Eyewire News: The Podcast · host Eyewire News
Glaukos submits a new drug application to the FDA for its next-generation cross-linking therapy; Regeneron releases phase 3 results for Eylea HD for RVO; and Regeneron acquires a clinical stage biotech making ocular delivery technology for retinal disorders. Learn more about your ad choices. Visit megaphone.fm/adchoices
NOW PLAYING
Glaukos Submits NDA for Epi-On CLX Candidate
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m